Vir Biotechnology Inc Cash Flow-to-Debt Ratio
Vir Biotechnology Inc cash flow-to-debt ratio. Vir Biotechnology Inc (VIR) has a Cash Flow-to-Debt Ratio of 0.53x as of June 2026, meaning its operating cash flow of $123.33 Million could theoretically repay 1% of its total liabilities ($232.31 Million) in one year. Check VIR total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Vir Biotechnology Inc (2017–2025)
Cash flow-to-debt ratio of Vir Biotechnology Inc from 2017 to 2025. Historical debt coverage capacity for Vir Biotechnology Inc across 9 annual periods. Check how high is Vir Biotechnology Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Vir Biotechnology Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
Vir Biotechnology Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Vir Biotechnology Inc. For the full cash flow conversion analysis, see Vir Biotechnology Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.65x | $-391.78 Million | $237.55 Million | ▲ +8.2% |
| 2024 | -1.80x | $-446.35 Million | $248.43 Million | ▲ +24.1% |
| 2023 | -2.37x | $-778.78 Million | $328.82 Million | ▼ -203.1% |
| 2022 | 2.30x | $1.66 Billion | $724.12 Million | ▲ +2621.5% |
| 2021 | -0.09x | $-47.59 Million | $522.42 Million | ▲ +90.4% |
| 2020 | -0.95x | $-190.94 Million | $201.91 Million | ▲ +35.7% |
| 2019 | -1.47x | $-129.63 Million | $88.13 Million | ▼ -479.6% |
| 2018 | -0.25x | $-94.10 Million | $370.77 Million | ▼ -22.5% |
| 2017 | -0.21x | $-66.38 Million | $320.48 Million | — |